Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports | Zendy

Paul S. White | Zendy; Anita Pudusseri | Zendy; Stephanie L. Lee | Zendy; Omar Eton | Zendy

Open Access

Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF^V600E Mutated Papillary Thyroid Cancer: Two Case Reports

Author(s) -

Paul S. White,

Anita Pudusseri,

Stephanie L. Lee,

Omar Eton

Publication year - 2017

Publication title -

thyroid

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.918

H-Index - 142

eISSN - 1557-9077

pISSN - 1050-7256

DOI - 10.1089/thy.2017.0106

Subject(s) - dosing , medicine , trametinib , dabrafenib , thyroid cancer , tolerability , papillary thyroid cancer , oncology , clinical trial , cancer , surgery , adverse effect , vemurafenib , metastatic melanoma , mapk/erk pathway , microbiology and biotechnology , kinase , biology

A multi-institutional, randomized phase II trial of continuous dosing of dabrafenib with or without trametinib is ongoing in metastatic thyroid cancer. Preclinical evidence and emerging clinical experience in other cancers support evaluating intermittent dosing of these two agents to achieve more durable response, while being better tolerated and more cost effective.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research